Activation of MET promotes resistance to sorafenib in hepatocellular carcinoma cells via the AKT/ERK1/2-EGR1 pathway

Sorafenib is an oral multikinase inhibitor that has become an established therapeutic approach in advanced hepatocellular carcinoma (HCC). However, the benefit of sorafenib in clinical therapy is often affected by drug resistance. Therefore, it is important to explore the mechanisms underlying soraf...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Qing-Feng Xiang, Mei-Xiao Zhan, Yong Li, Hui Liang, Cong Hu, Yao-Ming Huang, Jing Xiao, Xu He, Yong-Jie Xin, Min-Shan Chen, Li-Gong Lu
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis Group 2019-12-01
Colecção:Artificial Cells, Nanomedicine, and Biotechnology
Assuntos:
Sorafenib
resistance
MET
hepatocellular carcinoma
Acesso em linha:https://www.tandfonline.com/doi/10.1080/21691401.2018.1543195
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados